REPROCELL
Cite as: Japan IR Index, REPROCELL (4978), methodology GNT-BDS v1.1.1, reviewed 2026-10-23.
Findings and sources as of the review date shown. The company’s English disclosure may have changed since.
Where to start
Chosen from this company's lowest answers, easiest first. A quick fix uses material the company already has; a translation fix is usually met by translating a Japanese document (our note says whether this company has one). Questions that need a budget or a board decision are left out. Suggestions drawn from the research, separate from the scores.
F6 Multi-year financial data file (Excel or CSV) downloadable in English 0/5 Quick fix
Post the financial figures the company already publishes as an Excel or CSV file with English labels.
G3 Board skills matrix published in English 0/5 Quick fix
Publish the skills matrix from the Japanese AGM notice in English.
G6 Shareholder vote results disclosed in English 0/5 Quick fix
Publish the vote counts from the Japanese extraordinary report in English.
O7 Named English IR contact published 2/5 Quick fix
Link a dedicated IR contact (form, address or e-mail) from the English IR section.
English disclosure assessment
All 34 questions reviewed by the editor against the public documents; this is not an independent audit. 10 answers corrected after re-checks (research errors) on 23 Oct 2026. These are changes to our record, not to the company’s disclosure. Changes to this record →
Compared with peers
| Peer group | Median | This company |
|---|---|---|
| Same sector (Chemicals) | 82.8 | 18 of 18 |
| Same size band (Under ¥100bn) | 51.4 | 18 of 25 |
Compared with the companies covered here, not the whole market. Sector is the TSE 33-sector classification; market cap is from kabutan.jp, 19 Oct 2026; it only sets the size band, plays no part in the score, and is refreshed once a quarter. Ties share the higher rank.
Out of 100.
Of the 34 questions reviewed, 19 scored 3 or more and 13 found no qualifying English materials within the stated review scope. Read each score with its source and scope below.
Findings by question
F1Quarterly and full-year results summaries (tanshin) published in English4/5
An English tanshin for every quarter from Q1 FY3/2026 to Q1 FY3/2027 (IR Library), each with its qualitative section, statements and segment note. Not on the Japanese cycle: Q3 FY3/2026 (12 Feb 2026) and Q1 FY3/2027 (13 Aug 2026) came the same day, but the FY3/2026 English file is dated 14 Jun against the Japanese 14 May, and the Q1 and H1 FY3/2026 English files were created on 20 Feb 2026, three to six months after the Japanese. Every period, late for some, so 4. Source document →
F2English results summary is a full translation, not an excerpt5/5
The English Q1 FY3/2027 tanshin (13 Aug 2026) is 19 pages against 18 in Japanese: summary pages, qualitative information with the forecast explanation, balance sheet, income and comprehensive income statements, and the notes (going concern, equity, cash flows, segment information, subsequent events, going-concern events). Whole, so 5. Source document →
F3Financial statements including notes available in English5/5
Statements with notes for the latest period in the English Q1 FY3/2027 tanshin (balance sheet, income and comprehensive income, notes including the segment note); the English FY3/2026 tanshin adds the cash-flow statement and full year-end notes. So 5. Source document →
F4Annual securities report available in English in any form0/5
reprocell.com/investor-relations/library lists quarterly and annual results briefings only; no distinct annual securities report document found. Checked via browser 21 Sep 2026.
F5Segment revenue and profit disclosed in English, consistent definitions5/5
Sales and segment profit or loss for the Research Support and Medical businesses in every English tanshin, with sales by country. The FY3/2026 tanshin defines both segments and states that segment profit is on an ordinary-profit basis; the definitions are the same in each period. So 5. Source document →
F6Multi-year financial data file (Excel or CSV) downloadable in English0/5
The Q1 FY2027 consolidated financial results PDF (reprocell.com, filed 13 Aug 2026) presents figures in-document only; no downloadable Excel/CSV file found on the site.
F7Guidance disclosed in English with the basis explained5/5
The English FY3/2026 tanshin's 'Future Outlook' gives the FY3/2027 forecast (sales ¥2,629m, operating loss ¥630m) with its basis: exchange rates of ¥150/US$, ¥200/£ and ¥1.72/INR, a stated Middle East assumption, and the outlook by segment in words. The revision of 12 Feb 2026 is in English with its reason (US research budget cuts slowing orders). The September record gave 4. So 5. Source document →
F8English financial disclosure current to the latest Japanese filing period5/5
English results cover Q1 FY3/2027 (three months to 30 Jun 2026), the latest Japanese period. So 5.
S1Medium-term management plan in English with numerical targets0/5
No medium-term plan with numerical targets in English. The Japanese side publishes the Growth-market 'business plan and growth potential' document (事業計画及び成長可能性に関する事項, latest June 2026) in Japanese only; the English Growth Strategy page describes strategic pillars and pipeline programmes qualitatively, with no revenue, profit or return targets. Re-checked 23 Oct 2026.
S2IR presentations published in English3/5
Japanese decks come twice a year (H1 and full year; archive back to FY3/2017). In English only the FY3/2026 deck is published ('Financial Results Briefing for the Fiscal Year Ended March 2026', IR Library); there is no English H1 FY3/2026 deck in the library or IR News, and the post-AGM business briefing deck (26 Jun 2026) is Japanese only. Full year only, so 3. Source document →
S3English equity-story or investment-highlights page4/5
The English IR top (CEO message) and the Growth Strategy page set out the case: three business pillars, four pipeline products with their stage, GMP sites in Japan, the US and Europe, mRNA reprogramming and HLA-knockout technology. The only figures are market sizes (about ¥50-53 trillion by 2050). Dedicated and specific, mostly qualitative, so 4. Source document →
S4Growth drivers identified and quantified in English4/5
The Growth Strategy page and the English tanshin name the drivers and their stage: Stemchymal (approval filed in Japan on 24 Jun 2026), iPS-derived glial cells for ALS, TIL therapy at Keio, and GPC1 CAR-T. Market sizes are given (about ¥17 trillion in 2030, ¥53 trillion by 2050) but no revenue contributions. Named, some quantified, so 4. Source document →
S5Results-briefing transcripts or Q&A published in English0/5
No results-briefing transcript or Q&A in English, and none in Japanese either: the Japanese side publishes the briefing deck and a briefing video (決算説明会動画), with no written Q&A since a 2017 summary. Neither language publishes one. Re-checked 23 Oct 2026.
S6Integrated or annual report available in English0/5
No integrated or annual report identified on reprocell.com/investor-relations/library on 21 Sep 2026; the library lists quarterly/annual results briefings only.
S7Progress against the previous plan, including misses, explained in English0/5
No English review of progress against a plan. The Japanese business-plan document (June 2026) carries the plan and its progress; it has no English version. Re-checked 23 Oct 2026.
G1Corporate governance report available in English0/5
No corporate governance report listed on reprocell.com/investor-relations/library on 21 Sep 2026.
G2Director biographies in English with tenure, expertise and independence0/5
Same absence as G1: no corporate governance page or report exists anywhere on reprocell.com's investor-relations section, so no director biographies are published. Checked via browser 21 Sep 2026.
G3Board skills matrix published in English0/5
Same absence rules out any board skills matrix. Checked via browser 21 Sep 2026.
G4Executive remuneration structure and its performance linkage explained in English0/5
Same absence rules out any remuneration-structure disclosure. Checked via browser 21 Sep 2026.
G5AGM notice in English with sufficient lead time to vote0/5
reprocell.com/investor-relations/shareholder-services gives only generic administrative info (registrar contact, dividend record dates, 'AGM held late June each year') -- no actual convocation notice document. Checked via browser 21 Sep 2026.
G6Shareholder vote results disclosed in English0/5
Same shareholder-services page has no vote-results document, only administrative contact info. Checked via browser 21 Sep 2026.
G7Cross-shareholdings in English with reduction schedule and rationale0/5
Same absence rules out any cross-shareholding disclosure. Checked via browser 21 Sep 2026.
O1English IR section reachable within two clicks of the English homepage4/5
'Investors' in the English homepage's top bar is a menu button, not a link; clicking it opens a panel whose first entry, 'Investor Relations', leads to the IR top. No IR link in the homepage body or footer. Two clicks, so 4. Source document →
O2English document links resolve to English documents4/5
Sampled the seven English IR Library links (five tanshin from Q1 FY3/2026 to Q1 FY3/2027, the FY3/2026 deck, and a service brochure) and five IR News notices. All open as English documents except the brochure, 'REPROCELL Clinical iPSC Service (Chinese)', in Chinese and labelled so in its title. One non-English document, labelled, so 4. Source document →
O3English IR archive free of dead links5/5
The same twelve links all open (checked 23 Oct 2026). So 5. Source document →
O4English IR pages render without blank JavaScript failures5/5
The English IR pages render their content in the browser: IR top, Growth Strategy, Performance Highlights (seven years of charts), IR News, IR Library, IR Policy, Disclaimer, Information about Stocks and Shareholder Services. So 5. Source document →
O5Single page listing all English IR documents by date and type3/5
No single list: the IR Library holds tanshin and the deck (undated), and IR News the dated notices and some results. Split across pages, so 3. Source document →
O6English archive genuinely populated, not an unverifiable shell4/5
English documents from June 2025 (Q1 FY3/2026 tanshin) to October 2026: five quarters of tanshin, one deck and IR News back to January 2026, with no older archive. At least a year, not several, so 4. Source document →
O7Named English IR contact published2/5
No IR contact route on the English site. The IR pages name no contact, Shareholder Services gives only the registrar's toll-free number, and 'Contact' leads to the general product-enquiry form with no IR option. The English tanshin header names Koji Yamane, GM of Corporate Management Dept., tel 045-475-3887. The Japanese IR pages have an IR enquiry form, in Japanese only. Named only in a document header, so 2. Source document →
R1Earnings materials published in English simultaneously with Japanese3/5
Q1 FY3/2027 tanshin 13 Aug in both languages (the Japanese side has no Q1 deck). FY3/2026: tanshin JA 14 May / EN 14 Jun, deck JA 8 Jun / EN 19 Jun (English file dates). H1 FY3/2026: tanshin JA 13 Nov 2025 / EN 20 Feb 2026, no English deck. Days to weeks late, so 3. Source document →
R2Median lag in days between Japanese and English statutory publication1/5
The English library is undated, so English PDF creation dates: Q1 FY3/27 tanshin JA 13 Aug / EN 13 Aug = 0; FY3/26 tanshin JA 14 May / EN 14 Jun = 31; 24th AGM notice JA 1 Jun, no English (>90); Annual Securities Report JA 26 Jun, no English (>90); Corporate Governance Report, no English (>90). Median over 90 days, so 1. Source document →
R3Timely disclosures published in English3/5
Twelve months of the Japanese IR news (23 Oct 2025 to 22 Oct 2026) against English IR News, which starts on 26 Jan 2026. The business and financing notices since January are in English the same day. Not in English IR News: the non-operating income notices (13 Nov 2025, 12 Feb, 14 May, 13 Aug 2026), the 14 May variance notice, the board's opposition to a shareholder proposal (11 Jun), the restricted-stock issue (3 Mar), the Cyto-Facto agreement and its correction (16 and 19 Jan), and the AMED notices of 5 and 9 Dec 2025; the English site search finds none of the income notices. Selected types only, so 3. Source document →
R4English disclosure free of machine-translation accuracy disclaimers5/5
No machine-translation notice on the rendered English IR pages, the IR disclaimer, or the English tanshin and October 2026 notices. So 5. Source document →
R5English version stated as authoritative, not subordinate to Japanese3/5
No prevailing-language statement on the English tanshin, the FY3/2026 deck or the English notices, and the IR Disclaimer says nothing either way. Silent, so 3. Source document →
Open a question for the reasoning and the document its score was read from. A zero means no qualifying English materials were located within the stated review scope as of 2026-10-23. Compare this question across companies →
Capital-policy review
No capital action has been reviewed for this company yet. The monitor covers a selection of companies and, within them, a selection of actions. See the companies covered →
Balance sheet and capital-policy indicators
No balance-sheet reading has been published for this company. See the companies covered →
Changes to this record
- Research error 23 October 2026 · F1: 5 → 4. The English tanshin covers every quarter, but not on the Japanese day: the FY3/2026 one came a month later and two FY3/2026 quarters months later.
- Research error 23 October 2026 · F5: 4 → 5. Sales and segment profit for both segments are in every English tanshin, with the segment definitions stated.
- Research error 23 October 2026 · F7: 4 → 5. The English forecast gives its basis (exchange-rate assumptions, outlook by segment) and the February 2026 revision explains its reason.
- Research error 23 October 2026 · S3: 5 → 4. The English growth-strategy pages are dedicated and specific, but the strengths are described in words; the only figures are market sizes.
- Research error 23 October 2026 · O1: 5 → 4. 'Investors' on the English homepage is a menu button, so the IR top is two clicks away.
- Research error 23 October 2026 · R3: 4 → 3. Business and financing notices are in English the same day, but income, variance, governance and some other notices are not.
- Research error 23 October 2026 · S2: 4 → 3. Only the full-year deck is in English; the Japanese side also publishes a half-year deck.
- Research error 23 October 2026 · S5: 3 → 0. Neither language publishes a briefing Q&A or transcript; the Japanese side posts a briefing video only.
- Research error 23 October 2026 · O3: 4 → 5. All twelve sampled English IR links open.
- Research error 23 October 2026 · O6: 5 → 4. The English archive runs from June 2025: at least a year, not several.
Every change is labelled as a research error, new evidence supplied, improved disclosure or a rule change, with its date and the previous score. Change log →
Scores assess how English information is published, not the quality of the business or its investment value. To report an error or a document we missed, see how to contact us.